Kyvera Therapeutics

Gilead-backed Kyverna Therapeutics aims for $857.3 mln valuation in upsized IPO
Reuters
Tue, 02/6/24 - 09:17 am
Kyvera Therapeutics
IPOs
Gilead Sciences
autoimmune diseases